Novavax Vaccine

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Full results from Nuvaxovid's pivotal phase III trial were published in December 2021. The vaccine requires two doses and is stable at 2 to 8 °C refrigerated temperatures. The most common side effects include headache, nausea or vomiting, muscle and joint pain, tenderness and pain at the injection site, tiredness and feeling unwell.